Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii
Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins ar...
Saved in:
Published in | Antimicrobial agents and chemotherapy Vol. 60; no. 6; pp. 3480 - 3488 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
01.06.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 0066-4804 1098-6596 |
DOI | 10.1128/AAC.00285-16 |
Cover
Abstract | Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of
Pseudomonas aeruginosa
to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant
Acinetobacter baumannii
, even resulting in a complete elimination of large inocula (≥10
8
CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of
A. baumannii
upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both
A. baumannii
and
P. aeruginosa
, two of the most life-threatening pathogens of the order
Pseudomonadales
. |
---|---|
AbstractList | Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula (≥10(8) CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa, two of the most life-threatening pathogens of the order Pseudomonadales. Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula ( greater than or equal to 108 CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa, two of the most life-threatening pathogens of the order Pseudomonadales. Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii , even resulting in a complete elimination of large inocula (≥10 8 CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa , two of the most life-threatening pathogens of the order Pseudomonadales . Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula (≥108 CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa, two of the most life-threatening pathogens of the order Pseudomonadales. |
Author | Schuermans, Joris Michiels, Jan Briers, Yves Lavigne, Rob Grymonprez, Barbara Govers, Sander K. Fauvart, Maarten Defraine, Valerie Aertsen, Abram |
Author_xml | – sequence: 1 givenname: Valerie surname: Defraine fullname: Defraine, Valerie organization: Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium – sequence: 2 givenname: Joris surname: Schuermans fullname: Schuermans, Joris organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium – sequence: 3 givenname: Barbara surname: Grymonprez fullname: Grymonprez, Barbara organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium – sequence: 4 givenname: Sander K. surname: Govers fullname: Govers, Sander K. organization: Laboratory of Food Microbiology, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium – sequence: 5 givenname: Abram surname: Aertsen fullname: Aertsen, Abram organization: Laboratory of Food Microbiology, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium – sequence: 6 givenname: Maarten surname: Fauvart fullname: Fauvart, Maarten organization: Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium – sequence: 7 givenname: Jan surname: Michiels fullname: Michiels, Jan organization: Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium – sequence: 8 givenname: Rob surname: Lavigne fullname: Lavigne, Rob organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium – sequence: 9 givenname: Yves orcidid: 0000-0001-7723-1040 surname: Briers fullname: Briers, Yves organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium, Laboratory of Applied Biotechnology, Department of Applied Biosciences, Ghent University, Ghent, Belgium |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27021321$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1rFTEUxYNU7GvrzrXMUqHTJjP53AjDo1ahoJTqNmQyd2rKTNImGeH99-b5WrGl4io5N78c7r3nAO354AGhNwSfENLI065bn2DcSFYT_gKtCFay5kzxPbTCmPOaSkz30UFKN7hopvArtN8I3JC2ISv0_WwcnTV2U4Wx6mJ20yY5v73VRLDKXBvnU64uIbmUjc-V8UP1FeJWQpGddR5y6I3NEKveLLPx3rkj9HI0U4LX9-ch-vbx7Gr9qb74cv553V3UhlGWa2ACBtkPQISiRDFKCbNSktYOQuC-x8qythRVTwWDgdieYjMwPsoWJHDVHqIPO9_bpZ9hsKWlaCZ9G91s4kYH4_TjF-9-6OvwU1MpVMtxMXh3bxDD3QIp69klC9NkPIQlaSKxFKRlrfg_KlTZKZOyKej7HWrS3OibsERftqAJ1tvIdIlM_45ME17Yt3-P8Kf3h4wK0OwAG0NKEUZtXTbZhe1EbvqX6_GTTw--z-K_AL5vsPY |
CitedBy_id | crossref_primary_10_1016_j_ijpharm_2020_119833 crossref_primary_10_1007_s10482_017_0912_9 crossref_primary_10_1080_1040841X_2020_1809346 crossref_primary_10_1111_1751_7915_13594 crossref_primary_10_1016_j_copbio_2020_08_014 crossref_primary_10_3390_foods14061075 crossref_primary_10_1128_CMR_00058_16 crossref_primary_10_1016_j_drup_2018_03_002 crossref_primary_10_1038_s41392_024_01866_5 crossref_primary_10_3390_microorganisms8060935 crossref_primary_10_1080_14787210_2016_1194754 crossref_primary_10_3390_antibiotics11111636 crossref_primary_10_1128_AAC_00024_19 crossref_primary_10_1039_D4MD00745J crossref_primary_10_7554_eLife_98266_3 crossref_primary_10_1080_1040841X_2020_1822278 crossref_primary_10_1016_j_ijbiomac_2024_132990 crossref_primary_10_1080_17460913_2024_2393003 crossref_primary_10_1093_infdis_jiae027 crossref_primary_10_3390_v11030268 crossref_primary_10_1016_j_ejmech_2024_116381 crossref_primary_10_1038_srep35382 crossref_primary_10_31083_FBL24478 crossref_primary_10_3389_fmicb_2018_03302 crossref_primary_10_3390_antibiotics10121497 crossref_primary_10_3390_v12111286 crossref_primary_10_1007_s12223_023_01046_y crossref_primary_10_1080_1040841X_2020_1825333 crossref_primary_10_1016_j_mib_2024_102433 crossref_primary_10_3390_v16050760 crossref_primary_10_1128_spectrum_01813_23 crossref_primary_10_1080_1040841X_2019_1600472 crossref_primary_10_7554_eLife_98266 crossref_primary_10_1007_s00203_024_04173_3 crossref_primary_10_3390_antibiotics7020029 crossref_primary_10_3389_fphar_2024_1385261 crossref_primary_10_1128_spectrum_04515_22 crossref_primary_10_3103_S0891416824700332 crossref_primary_10_1016_j_ijantimicag_2019_11_001 crossref_primary_10_3390_v17020200 crossref_primary_10_3389_fmicb_2018_00129 crossref_primary_10_3390_v15030679 crossref_primary_10_3390_antibiotics10030293 crossref_primary_10_1186_s13567_018_0563_5 crossref_primary_10_3390_v10040163 crossref_primary_10_3390_microorganisms12030629 crossref_primary_10_1021_acssynbio_7b00058 crossref_primary_10_3390_ph16091281 crossref_primary_10_1038_s41579_023_00993_0 crossref_primary_10_1016_j_molcel_2019_09_028 crossref_primary_10_4155_tde_2017_0040 crossref_primary_10_1016_j_biotechadv_2017_12_009 crossref_primary_10_1080_1040841X_2021_1939266 crossref_primary_10_1128_AAC_00836_17 crossref_primary_10_1007_s11262_020_01735_7 crossref_primary_10_1080_1040841X_2022_2125286 crossref_primary_10_36233_0372_9311_250 crossref_primary_10_3389_fcimb_2022_1035364 crossref_primary_10_1016_j_ijbiomac_2025_140463 crossref_primary_10_1016_j_micres_2021_126746 crossref_primary_10_1002_bit_28581 crossref_primary_10_3389_fmicb_2022_993990 crossref_primary_10_1080_1040841X_2023_2181056 crossref_primary_10_1126_sciadv_aaz1136 crossref_primary_10_1007_s00449_023_02938_6 crossref_primary_10_1016_j_pep_2018_12_002 crossref_primary_10_1007_s40121_021_00446_2 crossref_primary_10_1016_j_resmic_2023_104104 crossref_primary_10_1039_D1BM00423A crossref_primary_10_3390_antibiotics10101260 crossref_primary_10_2174_1871526523666230511142054 crossref_primary_10_1146_annurev_virology_092917_043544 crossref_primary_10_3390_antibiotics9020074 crossref_primary_10_3389_fmicb_2023_1170418 crossref_primary_10_1093_femsre_fux001 crossref_primary_10_1016_S0140_6736_24_02081_6 crossref_primary_10_1111_1751_7915_14465 crossref_primary_10_3390_antibiotics12061044 crossref_primary_10_3389_fcimb_2017_00055 crossref_primary_10_1146_annurev_chembioeng_060816_101612 crossref_primary_10_1128_spectrum_05261_22 crossref_primary_10_1248_bpb_b19_00914 crossref_primary_10_3389_fimmu_2018_02252 crossref_primary_10_3389_fmicb_2018_01778 crossref_primary_10_1371_journal_pone_0192507 crossref_primary_10_1016_j_ijantimicag_2017_08_027 crossref_primary_10_1016_j_tibtech_2018_04_006 crossref_primary_10_1146_annurev_bioeng_010220_095711 crossref_primary_10_1111_1751_7915_14513 crossref_primary_10_1021_acsinfecdis_1c00222 crossref_primary_10_1128_aac_02273_21 crossref_primary_10_3389_fcimb_2016_00194 crossref_primary_10_1038_nrmicro_2017_61 crossref_primary_10_3390_pharmaceutics16121542 crossref_primary_10_3390_v11030284 crossref_primary_10_1016_j_drup_2016_10_002 crossref_primary_10_1007_s00284_021_02662_y crossref_primary_10_1128_AEM_01515_21 |
Cites_doi | 10.1128/AAC.04641-14 10.3389/fmicb.2014.00542 10.1111/2049-632X.12174 10.4103/0974-777X.68538 10.1371/journal.pgen.1003269 10.1128/AAC.01597-13 10.1038/nature07742 10.1128/AAC.01701-13 10.1016/j.ijantimicag.2013.04.022 10.1093/infdis/jit637 10.1016/j.bbapap.2008.11.005 10.2217/fmb.15.8 10.1002/ddr.20329 10.1128/CMR.05041-11 10.1086/595977 10.1128/JCM.00547-06 10.1371/journal.pone.0084361 10.1128/AAC.00243-13 10.1128/AAC.01966-15 10.1016/j.ijantimicag.2015.03.001 10.4161/viru.19700 10.1042/BST20120209 10.1016/S0966-842X(00)01705-4 10.2174/138920312804871193 10.1126/science.1211037 10.1038/nature01026 10.2217/fmb.12.97 10.1128/AAC.01783-12 10.1128/AAC.02668-14 10.1128/IAI.01600-14 10.1016/B978-0-12-394438-2.00007-4 10.1086/653120 10.1128/AAC.00860-09 10.1111/1462-2920.12594 10.1128/AAC.00633-13 10.1007/s00253-011-3104-y 10.1128/AEM.02440-10 10.1128/JB.01651-09 10.1146/annurev.micro.112408.134306 10.1126/science.1066869 10.1371/journal.pone.0104853 10.1586/eri.13.12 10.1128/MMBR.00016-10 10.1126/science.1229858 10.1080/21597081.2015.1062590 10.1016/j.ijmm.2010.04.002 10.1128/mBio.01379-14 10.1099/jmm.0.030932-0 |
ContentType | Journal Article |
Copyright | Copyright © 2016, American Society for Microbiology. All Rights Reserved. Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7QL 7T7 8FD C1K FR3 P64 5PM |
DOI | 10.1128/AAC.00285-16 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Bacteriology Abstracts (Microbiology B) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE Engineering Research Database MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Art-175 against , Defraine et al Art-175 against Acinetobacter baumannii |
EISSN | 1098-6596 |
EndPage | 3488 |
ExternalDocumentID | PMC4879360 00285-16 27021321 10_1128_AAC_00285_16 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Fund for Scientific Research-Flanders grantid: 1517115N – fundername: Agency for Innovation by Science and Technology – fundername: KU Leuven Research Council grantid: IDO/09/010 – fundername: Fund for Scientific Research-Flanders grantid: FWO G047112N – fundername: KU Leuven Excellence Center Financing grantid: PF/2010/07 |
GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ CGR CUY CVF ECM EIF NPM - 0R 55 AAPBV ABFLS ADACO BXI HZ RHF ZA5 7X8 7QL 7T7 8FD C1K FR3 P64 5PM |
ID | FETCH-LOGICAL-a545t-e57ed8bde17941954415c8813cd770bb09c534419b475ed1cb40ad56f83e8e693 |
ISSN | 0066-4804 |
IngestDate | Thu Aug 21 14:00:17 EDT 2025 Fri Sep 05 04:57:47 EDT 2025 Fri Sep 05 10:11:13 EDT 2025 Tue Dec 28 13:59:19 EST 2021 Thu Apr 03 07:05:37 EDT 2025 Tue Jul 01 04:32:33 EDT 2025 Thu Apr 24 23:04:43 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | Copyright © 2016, American Society for Microbiology. All Rights Reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a545t-e57ed8bde17941954415c8813cd770bb09c534419b475ed1cb40ad56f83e8e693 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation Defraine V, Schuermans J, Grymonprez B, Govers SK, Aertsen A, Fauvart M, Michiels J, Lavigne R, Briers Y. 2016. Efficacy of Artilysin Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother 60:3480–3488. doi:10.1128/AAC.00285-16. |
ORCID | 0000-0001-7723-1040 |
OpenAccessLink | https://aac.asm.org/content/aac/60/6/3480.full.pdf |
PMID | 27021321 |
PQID | 1791325882 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4879360 proquest_miscellaneous_1808713537 proquest_miscellaneous_1791325882 asm2_journals_10_1128_AAC_00285_16 pubmed_primary_27021321 crossref_citationtrail_10_1128_AAC_00285_16 crossref_primary_10_1128_AAC_00285_16 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-06-01 |
PublicationDateYYYYMMDD | 2016-06-01 |
PublicationDate_xml | – month: 06 year: 2016 text: 2016-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Antimicrobial agents and chemotherapy |
PublicationTitleAbbrev | Antimicrob Agents Chemother |
PublicationTitleAlternate | Antimicrob Agents Chemother |
PublicationYear | 2016 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_3_50_2 Freimer EH (e_1_3_3_31_2) 1959; 110 e_1_3_3_16_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_33_2 e_1_3_3_10_2 e_1_3_3_40_2 e_1_3_3_5_2 e_1_3_3_7_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_44_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_32_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_6_2 e_1_3_3_8_2 e_1_3_3_28_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 23742833 - Int J Antimicrob Agents. 2013 Aug;42(2):141-8 22546906 - Virulence. 2012 May 1;3(3):243-50 10707065 - Trends Microbiol. 2000 Mar;8(3):120-8 19199531 - Infect Control Hosp Epidemiol. 2009 Mar;30(3):257-63 20927292 - J Glob Infect Dis. 2010 Sep;2(3):291-304 20504234 - Clin Infect Dis. 2010 Jul 1;51(1):79-84 20528688 - Annu Rev Microbiol. 2010;64:357-72 22096200 - Science. 2011 Nov 18;334(6058):982-6 20805405 - Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33 23629720 - Antimicrob Agents Chemother. 2013 Jul;57(7):3230-9 11739958 - Science. 2001 Dec 7;294(5549):2170-2 25857949 - Int J Antimicrob Agents. 2015 Jun;45(6):568-85 13824817 - J Exp Med. 1959 Dec 1;110:853-74 25360133 - Front Microbiol. 2014 Oct 16;5:542 23176506 - Biochem Soc Trans. 2012 Dec 1;40(6):1503-6 23483857 - PLoS Genet. 2013;9(2):e1003269 19100346 - Biochim Biophys Acta. 2009 May;1794(5):808-16 21459912 - J Med Microbiol. 2011 Jun;60(Pt 6):699-709 23305359 - Curr Protein Pept Sci. 2012 Dec;13(8):699-722 23030422 - Future Microbiol. 2012 Oct;7(10):1147-71 12192412 - Nature. 2002 Aug 22;418(6900):884-9 24100496 - Antimicrob Agents Chemother. 2013 Dec;57(12):6276-83 25142185 - Environ Microbiol. 2015 May;17(5):1586-99 19841146 - Antimicrob Agents Chemother. 2010 Jan;54(1):39-44 20452280 - Int J Med Microbiol. 2010 Aug;300(6):357-62 23288538 - Science. 2013 Jan 4;339(6115):91-5 26442196 - Bacteriophage. 2015 Jun 23;5(3):e1062590 22763634 - Clin Microbiol Rev. 2012 Jul;25(3):450-70 24752267 - Antimicrob Agents Chemother. 2014 Jul;58(7):3774-84 24189257 - Antimicrob Agents Chemother. 2014;58(1):518-26 25605353 - Antimicrob Agents Chemother. 2015 Apr;59(4):1983-91 25111143 - PLoS One. 2014 Aug 11;9(8):e104853 24987094 - MBio. 2014 Jul 01;5(4):e01379-14 25812461 - Future Microbiol. 2015;10(3):377-90 24391945 - PLoS One. 2013 Dec 31;8(12):e84361 19212404 - Nature. 2009 Feb 12;457(7231):849-53 16825400 - J Clin Microbiol. 2006 Jul;44(7):2630-4 24692291 - Pathog Dis. 2014 Jun;71(1):39-54 24891106 - Infect Immun. 2014 Aug;82(8):3417-25 21622798 - Appl Environ Microbiol. 2011 Jul;77(14):4878-85 23458769 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308 21264466 - Appl Microbiol Biotechnol. 2011 Apr;90(2):529-39 23229482 - Antimicrob Agents Chemother. 2013 Feb;57(2):1069-72 22748813 - Adv Virus Res. 2012;83:299-365 20935098 - J Bacteriol. 2010 Dec;192(23):6191-9 26574005 - Antimicrob Agents Chemother. 2015 Nov 16;60(1):592-9 24286983 - J Infect Dis. 2014 May 1;209(9):1469-78 23939892 - Antimicrob Agents Chemother. 2013 Nov;57(11):5239-46 Lafleur, MD, Qi, Q, Lewis, K (B46) 2010; 54 Nguyen, D, Joshi-Datar, A, Lepine, F, Bauerle, E, Olakanmi, O, Beer, K, McKay, G, Siehnel, R, Schafhauser, J, Wang, Y, Britigan, BE, Singh, PK (B8) 2011; 334 Cenens, W, Mebrhatu, MT, Makumi, A, Ceyssens, P-J, Lavigne, R, Van Houdt, R, Taddei, F, Aertsen, A (B18) 2013; 9 Tamma, PD, Cosgrove, SE, Maragakis, LL (B41) 2012; 25 Wakamoto, Y, Dhar, N, Chait, R, Schneider, K, Signorino-Gelo, F, Leibler, S, McKinney, JD (B9) 2013; 339 Freimer, EH, Krause, RM, McCarty, M (B30) 1959; 110 Lai, M-J, Soo, P-C, Lin, N-T, Hu, A, Chen, Y-J, Chen, L-K, Chang, K-C (B37) 2013; 42 Schuch, R, Lee, HM, Schneider, BC, Sauve, KL, Law, C, Khan, BK, Rotolo, JA, Horiuchi, Y, Couto, DE, Raz, A, Fischetti, VA, Huang, DB, Nowinski, RC, Wittekind, M (B42) 2014; 209 Potron, A, Poirel, L, Nordmann, P (B2) 2015; 45 Bhargava, N, Sharma, P, Capalash, N (B25) 2014; 82 Nelson, DC, Schmelcher, M, Rodriguez-Rubio, L, Klumpp, J, Pritchard, DG, Dong, S, Donovan, DM (B33) 2012; 83 Drulis-Kawa, Z, Majkowska-Skrobek, G, Maciejewska, B, Delattre, A-S, Lavigne, R (B29) 2012; 13 Fishbain, J, Peleg, AY (B40) 2010; 51 Lewis, K (B6) 2010; 64 Schmelcher, M, Donovan, DM, Loessner, MJ (B34) 2012; 7 Lood, R, Winer, BY, Pelzek, AJ, Diez-Martinez, R, Thandar, M, Euler, CW, Schuch, R, Fischetti, VA (B38) 2015; 59 Loeffler, JM (B48) 2001; 294 Manchanda, V, Sanchaita, S, Singh, N (B28) 2010; 2 Briers, Y, Walmagh, M, Van Puyenbroeck, V, Cornelissen, A, Cenens, W, Aertsen, A, Oliveira, H, Azeredo, J, Verween, G, Pirnay, J-P, Miller, S, Volckaert, G, Lavigne, R (B11) 2014; 5 Briers, Y, Lavigne, R (B13) 2015; 10 Merabishvili, M, Vandenheuvel, D, Kropinski, AM, Mast, J, De Vos, D, Verbeken, G, Noben, J-P, Lavigne, R, Vaneechoutte, M, Pirnay, J-P (B15) 2014; 9 Davies, J, Davies, D (B27) 2010; 74 Kim, DH, Choi, J-Y, Kim, HW, Kim, SH, Chung, DR, Peck, KR, Thamlikitkul, V, So, TM-K, Yasin, RMD, Hsueh, P-R, Carlos, CC, Hsu, LY, Buntaran, L, Lalitha, MK, Song, J-H, Ko, KS (B21) 2013; 57 Beceiro, A, Moreno, A, Fernandez, N, Vallejo, JA, Aranda, J, Adler, B, Harper, M, Boyce, JD, Bou, G (B19) 2014; 58 Fischetti, VA (B32) 2010; 300 Schuch, R, Nelson, D, Fischetti, VA (B49) 2002; 418 Oechslin, F, Daraspe, J, Giddey, M, Moreillon, P, Resch, G (B39) 2013; 57 Orman, MA, Brynildsen, MP (B7) 2013; 57 Yang, H, Yu, J, Wei, H (B31) 2014; 5 Barth, VC, Rodrigues, BÁ, Bonatto, GD, Gallo, SW, Pagnussatti, VE, Ferreira, CAS, de Oliveira, SD (B5) 2013; 8 Howard, A, O'Donoghue, M, Feeney, A, Sleator, RD (B23) 2012; 3 Valencia, R, Arroyo, LA, Conde, M, Aldana, JM, Torres, M-J, Fernandez-Cuenca, F, Garnacho-Montero, J, Cisneros, JM, Ortiz, C, Pachon, J, Aznar, J (B1) 2009; 30 Pendleton, JN, Gorman, SP, Gilmore, BF (B3) 2013; 11 Saule, M, Samuelsen, O, Dumpis, U, Sundsfjord, A, Karlsone, A, Balode, A, Miklasevics, E, Karah, N (B22) 2013; 57 Delcour, AH (B4) 2009; 1794 Liebens, V, Defraine, V, Van der Leyden, A, De Groote, VN, Fierro, C, Beullens, S, Verstraeten, N, Kint, C, Jans, A, Frangipani, E, Visca, P, Marchal, K, Versées, W, Fauvart, M, Michiels, J (B17) 2014; 71 Lai, M-J, Lin, N-T, Hu, A, Soo, P-C, Chen, L-K, Chen, L-H, Chang, K-C (B36) 2011; 90 Turton, JF, Kaufmann, ME, Gill, MJ, Pike, R, Scott, PT, Fishbain, J, Craft, D, Deye, G, Riddell, S, Lindler, LE, Pitt, TL (B24) 2006; 44 Chen, X, Zhang, M, Zhou, C, Kallenbach, NR, Ren, D (B16) 2011; 77 Roach, DR, Donovan, DM (B35) 2015; 5 Young, I, Wang, I, Roof, WD (B12) 2000; 8 Leaver, M, Dominguez-Cuevas, P, Coxhead, JM, Daniel, RA, Errington, J (B44) 2009; 457 Fauvart, M, De Groote, VN, Michiels, J (B10) 2011; 60 Dawson, RM, Liu, C-Q (B26) 2009; 70 Briers, Y, Walmagh, M, Grymonprez, B, Biebl, M, Pirnay, JP, Defraine, V, Michiels, J, Cenens, W, Aertsen, A, Miller, S, Lavigne, R (B14) 2014; 58 Cambré, A, Zimmermann, M, Sauer, U, Vivijs, B, Cenens, W, Michiels, CW, Aertsen, A, Loessner, MJ, Noben, J-P, Ayala, JA, Lavigne, R, Briers, Y (B45) 2015; 17 Oddo, A, Thomsen, TT, Kjelstrup, S, Gorey, C, Franzyk, H, Frimodt-Moller, N, Lobner-Olesen, A, Hansen, PR (B20) 2016; 60 Lukacik, P, Barnard, TJ, Buchanan, SK (B43) 2012; 40 Mulcahy, LR, Burns, JL, Lory, S, Lewis, K (B47) 2010; 192 |
References_xml | – ident: e_1_3_3_39_2 doi: 10.1128/AAC.04641-14 – ident: e_1_3_3_32_2 doi: 10.3389/fmicb.2014.00542 – ident: e_1_3_3_18_2 doi: 10.1111/2049-632X.12174 – ident: e_1_3_3_29_2 doi: 10.4103/0974-777X.68538 – ident: e_1_3_3_19_2 doi: 10.1371/journal.pgen.1003269 – ident: e_1_3_3_20_2 doi: 10.1128/AAC.01597-13 – ident: e_1_3_3_45_2 doi: 10.1038/nature07742 – ident: e_1_3_3_40_2 doi: 10.1128/AAC.01701-13 – ident: e_1_3_3_38_2 doi: 10.1016/j.ijantimicag.2013.04.022 – ident: e_1_3_3_43_2 doi: 10.1093/infdis/jit637 – ident: e_1_3_3_5_2 doi: 10.1016/j.bbapap.2008.11.005 – ident: e_1_3_3_14_2 doi: 10.2217/fmb.15.8 – ident: e_1_3_3_27_2 doi: 10.1002/ddr.20329 – ident: e_1_3_3_42_2 doi: 10.1128/CMR.05041-11 – ident: e_1_3_3_2_2 doi: 10.1086/595977 – ident: e_1_3_3_25_2 doi: 10.1128/JCM.00547-06 – ident: e_1_3_3_6_2 doi: 10.1371/journal.pone.0084361 – ident: e_1_3_3_8_2 doi: 10.1128/AAC.00243-13 – ident: e_1_3_3_21_2 doi: 10.1128/AAC.01966-15 – ident: e_1_3_3_3_2 doi: 10.1016/j.ijantimicag.2015.03.001 – ident: e_1_3_3_24_2 doi: 10.4161/viru.19700 – ident: e_1_3_3_44_2 doi: 10.1042/BST20120209 – ident: e_1_3_3_13_2 doi: 10.1016/S0966-842X(00)01705-4 – ident: e_1_3_3_30_2 doi: 10.2174/138920312804871193 – ident: e_1_3_3_9_2 doi: 10.1126/science.1211037 – ident: e_1_3_3_50_2 doi: 10.1038/nature01026 – ident: e_1_3_3_35_2 doi: 10.2217/fmb.12.97 – volume: 110 start-page: 853 year: 1959 ident: e_1_3_3_31_2 article-title: Studies of L forms and protoplasts of group A streptococci. I publication-title: Isolation, growth, and bacteriologic characteristics. J Exp Med – ident: e_1_3_3_23_2 doi: 10.1128/AAC.01783-12 – ident: e_1_3_3_15_2 doi: 10.1128/AAC.02668-14 – ident: e_1_3_3_26_2 doi: 10.1128/IAI.01600-14 – ident: e_1_3_3_34_2 doi: 10.1016/B978-0-12-394438-2.00007-4 – ident: e_1_3_3_41_2 doi: 10.1086/653120 – ident: e_1_3_3_47_2 doi: 10.1128/AAC.00860-09 – ident: e_1_3_3_46_2 doi: 10.1111/1462-2920.12594 – ident: e_1_3_3_22_2 doi: 10.1128/AAC.00633-13 – ident: e_1_3_3_37_2 doi: 10.1007/s00253-011-3104-y – ident: e_1_3_3_17_2 doi: 10.1128/AEM.02440-10 – ident: e_1_3_3_48_2 doi: 10.1128/JB.01651-09 – ident: e_1_3_3_7_2 doi: 10.1146/annurev.micro.112408.134306 – ident: e_1_3_3_49_2 doi: 10.1126/science.1066869 – ident: e_1_3_3_16_2 doi: 10.1371/journal.pone.0104853 – ident: e_1_3_3_4_2 doi: 10.1586/eri.13.12 – ident: e_1_3_3_28_2 doi: 10.1128/MMBR.00016-10 – ident: e_1_3_3_10_2 doi: 10.1126/science.1229858 – ident: e_1_3_3_36_2 doi: 10.1080/21597081.2015.1062590 – ident: e_1_3_3_33_2 doi: 10.1016/j.ijmm.2010.04.002 – ident: e_1_3_3_12_2 doi: 10.1128/mBio.01379-14 – ident: e_1_3_3_11_2 doi: 10.1099/jmm.0.030932-0 – reference: 25812461 - Future Microbiol. 2015;10(3):377-90 – reference: 23305359 - Curr Protein Pept Sci. 2012 Dec;13(8):699-722 – reference: 23030422 - Future Microbiol. 2012 Oct;7(10):1147-71 – reference: 10707065 - Trends Microbiol. 2000 Mar;8(3):120-8 – reference: 20528688 - Annu Rev Microbiol. 2010;64:357-72 – reference: 22096200 - Science. 2011 Nov 18;334(6058):982-6 – reference: 21622798 - Appl Environ Microbiol. 2011 Jul;77(14):4878-85 – reference: 16825400 - J Clin Microbiol. 2006 Jul;44(7):2630-4 – reference: 24100496 - Antimicrob Agents Chemother. 2013 Dec;57(12):6276-83 – reference: 23939892 - Antimicrob Agents Chemother. 2013 Nov;57(11):5239-46 – reference: 24391945 - PLoS One. 2013 Dec 31;8(12):e84361 – reference: 22748813 - Adv Virus Res. 2012;83:299-365 – reference: 25142185 - Environ Microbiol. 2015 May;17(5):1586-99 – reference: 25360133 - Front Microbiol. 2014 Oct 16;5:542 – reference: 19199531 - Infect Control Hosp Epidemiol. 2009 Mar;30(3):257-63 – reference: 24752267 - Antimicrob Agents Chemother. 2014 Jul;58(7):3774-84 – reference: 25857949 - Int J Antimicrob Agents. 2015 Jun;45(6):568-85 – reference: 19100346 - Biochim Biophys Acta. 2009 May;1794(5):808-16 – reference: 20935098 - J Bacteriol. 2010 Dec;192(23):6191-9 – reference: 13824817 - J Exp Med. 1959 Dec 1;110:853-74 – reference: 19841146 - Antimicrob Agents Chemother. 2010 Jan;54(1):39-44 – reference: 20805405 - Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33 – reference: 21459912 - J Med Microbiol. 2011 Jun;60(Pt 6):699-709 – reference: 20504234 - Clin Infect Dis. 2010 Jul 1;51(1):79-84 – reference: 22763634 - Clin Microbiol Rev. 2012 Jul;25(3):450-70 – reference: 23288538 - Science. 2013 Jan 4;339(6115):91-5 – reference: 24987094 - MBio. 2014 Jul 01;5(4):e01379-14 – reference: 23229482 - Antimicrob Agents Chemother. 2013 Feb;57(2):1069-72 – reference: 20927292 - J Glob Infect Dis. 2010 Sep;2(3):291-304 – reference: 23742833 - Int J Antimicrob Agents. 2013 Aug;42(2):141-8 – reference: 20452280 - Int J Med Microbiol. 2010 Aug;300(6):357-62 – reference: 25111143 - PLoS One. 2014 Aug 11;9(8):e104853 – reference: 23483857 - PLoS Genet. 2013;9(2):e1003269 – reference: 24692291 - Pathog Dis. 2014 Jun;71(1):39-54 – reference: 21264466 - Appl Microbiol Biotechnol. 2011 Apr;90(2):529-39 – reference: 24891106 - Infect Immun. 2014 Aug;82(8):3417-25 – reference: 23629720 - Antimicrob Agents Chemother. 2013 Jul;57(7):3230-9 – reference: 23176506 - Biochem Soc Trans. 2012 Dec 1;40(6):1503-6 – reference: 12192412 - Nature. 2002 Aug 22;418(6900):884-9 – reference: 19212404 - Nature. 2009 Feb 12;457(7231):849-53 – reference: 25605353 - Antimicrob Agents Chemother. 2015 Apr;59(4):1983-91 – reference: 26574005 - Antimicrob Agents Chemother. 2015 Nov 16;60(1):592-9 – reference: 11739958 - Science. 2001 Dec 7;294(5549):2170-2 – reference: 22546906 - Virulence. 2012 May 1;3(3):243-50 – reference: 23458769 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308 – reference: 24286983 - J Infect Dis. 2014 May 1;209(9):1469-78 – reference: 26442196 - Bacteriophage. 2015 Jun 23;5(3):e1062590 – reference: 24189257 - Antimicrob Agents Chemother. 2014;58(1):518-26 – volume: 300 start-page: 357 year: 2010 end-page: 362 ident: B32 article-title: Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens publication-title: Int J Med Microbiol doi: 10.1016/j.ijmm.2010.04.002 – volume: 10 start-page: 377 year: 2015 end-page: 390 ident: B13 article-title: Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria publication-title: Future Microbiol doi: 10.2217/fmb.15.8 – volume: 57 start-page: 5239 year: 2013 end-page: 5246 ident: B21 article-title: Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00633-13 – volume: 7 start-page: 1147 year: 2012 end-page: 1171 ident: B34 article-title: Bacteriophage endolysins as novel antimicrobials publication-title: Future Microbiol doi: 10.2217/fmb.12.97 – volume: 57 start-page: 6276 year: 2013 end-page: 6283 ident: B39 article-title: In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01701-13 – volume: 418 start-page: 884 year: 2002 end-page: 889 ident: B49 article-title: A bacteriolytic agent that detects and kills Bacillus anthracis publication-title: Nature doi: 10.1038/nature01026 – volume: 82 start-page: 3417 year: 2014 end-page: 3425 ident: B25 article-title: Pyocyanin stimulates quorum sensing-mediated tolerance to oxidative stress and increases persister cell populations in Acinetobacter baumannii publication-title: Infect Immun doi: 10.1128/IAI.01600-14 – volume: 77 start-page: 4878 year: 2011 end-page: 4885 ident: B16 article-title: Control of bacterial persister cells by Trp/Arg-containing antimicrobial peptides publication-title: Appl Environ Microbiol doi: 10.1128/AEM.02440-10 – volume: 44 start-page: 2630 year: 2006 end-page: 2634 ident: B24 article-title: Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict publication-title: J Clin Microbiol doi: 10.1128/JCM.00547-06 – volume: 83 start-page: 299 year: 2012 end-page: 365 ident: B33 article-title: Endolysins as antimicrobials publication-title: Adv Virus Res doi: 10.1016/B978-0-12-394438-2.00007-4 – volume: 457 start-page: 849 year: 2009 end-page: 853 ident: B44 article-title: Life without a wall or division machine in Bacillus subtilis publication-title: Nature doi: 10.1038/nature07742 – volume: 71 start-page: 39 year: 2014 end-page: 54 ident: B17 article-title: A putative de-N-acetylase of the PIG-L superfamily affects fluoroquinolone tolerance in Pseudomonas aeruginosa publication-title: Pathog Dis doi: 10.1111/2049-632X.12174 – volume: 57 start-page: 3230 year: 2013 end-page: 3239 ident: B7 article-title: Dormancy is not necessary or sufficient for bacterial persistence publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00243-13 – volume: 110 start-page: 853 year: 1959 end-page: 874 ident: B30 article-title: Studies of L forms and protoplasts of group A streptococci. I publication-title: Isolation, growth, and bacteriologic characteristics. J Exp Med – volume: 5 start-page: e1062590 year: 2015 ident: B35 article-title: Antimicrobial bacteriophage-derived proteins and therapeutic applications publication-title: Bacteriophage doi: 10.1080/21597081.2015.1062590 – volume: 1794 start-page: 808 year: 2009 end-page: 816 ident: B4 article-title: Outer membrane permeability and antibiotic resistance publication-title: Biochim Biophys Acta doi: 10.1016/j.bbapap.2008.11.005 – volume: 5 start-page: e01379-14 year: 2014 ident: B11 article-title: Engineered endolysin-based “artilysins” to combat multidrug-resistant gram-negative pathogens publication-title: mBio doi: 10.1128/mBio.01379-14 – volume: 9 start-page: e1003269 year: 2013 ident: B18 article-title: Expression of a novel P22 ORFan gene reveals the phage carrier state in Salmonella typhimurium publication-title: PLoS Genet doi: 10.1371/journal.pgen.1003269 – volume: 334 start-page: 982 year: 2011 end-page: 986 ident: B8 article-title: Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria publication-title: Science doi: 10.1126/science.1211037 – volume: 60 start-page: 699 year: 2011 end-page: 709 ident: B10 article-title: Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies publication-title: J Med Microbiol doi: 10.1099/jmm.0.030932-0 – volume: 51 start-page: 79 year: 2010 end-page: 84 ident: B40 article-title: Treatment of Acinetobacter infections publication-title: Clin Infect Dis doi: 10.1086/653120 – volume: 70 start-page: 481 year: 2009 end-page: 498 ident: B26 article-title: Cathelicidin peptide SMAP-29: comprehensive review of its properties and potential as a novel class of antibiotics publication-title: Drug Dev Res doi: 10.1002/ddr.20329 – volume: 57 start-page: 1069 year: 2013 end-page: 1072 ident: B22 article-title: Dissemination of a carbapenem-resistant Acinetobacter baumannii strain belonging to international clone II/sequence type 2 and harboring a novel AbaR4-like resistance island in Latvia publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01783-12 – volume: 42 start-page: 141 year: 2013 end-page: 148 ident: B37 article-title: Identification and characterisation of the putative phage-related endolysins through full genome sequence analysis in Acinetobacter baumannii ATCC 17978 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2013.04.022 – volume: 9 start-page: e104853 year: 2014 ident: B15 article-title: Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii publication-title: PLoS One doi: 10.1371/journal.pone.0104853 – volume: 8 start-page: e84361 year: 2013 ident: B5 article-title: Heterogeneous persister cells formation in Acinetobacter baumannii publication-title: PLoS One doi: 10.1371/journal.pone.0084361 – volume: 2 start-page: 291 year: 2010 end-page: 304 ident: B28 article-title: Multidrug resistant Acinetobacter publication-title: J Glob Infect Dis doi: 10.4103/0974-777X.68538 – volume: 294 start-page: 2170 year: 2001 end-page: 2172 ident: B48 article-title: Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase publication-title: Science doi: 10.1126/science.1066869 – volume: 13 start-page: 699 year: 2012 end-page: 722 ident: B29 article-title: Learning from bacteriophages—advantages and limitations of phage and phage-encoded protein applications publication-title: Curr Protein Pept Sci doi: 10.2174/138920312804871193 – volume: 25 start-page: 450 year: 2012 end-page: 470 ident: B41 article-title: Combination therapy for treatment of infections with gram-negative bacteria publication-title: Clin Microbiol Rev doi: 10.1128/CMR.05041-11 – volume: 58 start-page: 3774 year: 2014 end-page: 3784 ident: B14 article-title: Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02668-14 – volume: 90 start-page: 529 year: 2011 end-page: 539 ident: B36 article-title: Antibacterial activity of Acinetobacter baumannii phage varphiAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria publication-title: Appl Microbiol Biotechnol doi: 10.1007/s00253-011-3104-y – volume: 209 start-page: 1469 year: 2014 end-page: 1478 ident: B42 article-title: Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia publication-title: J Infect Dis doi: 10.1093/infdis/jit637 – volume: 54 start-page: 39 year: 2010 end-page: 44 ident: B46 article-title: Patients with long-term oral carriage harbor high-persister mutants of Candida albicans publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00860-09 – volume: 60 start-page: 592 year: 2016 end-page: 599 ident: B20 article-title: An all-D amphipathic undecapeptide shows promising activity against colistin-resistant strains of Acinetobacter baumannii and a dual mode of action publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01966-15 – volume: 74 start-page: 417 year: 2010 end-page: 433 ident: B27 article-title: Origins and evolution of antibiotic resistance publication-title: Microbiol Mol Biol Rev doi: 10.1128/MMBR.00016-10 – volume: 5 start-page: 542 year: 2014 ident: B31 article-title: Engineered bacteriophage lysins as novel anti-infectives publication-title: Front Microbiol doi: 10.3389/fmicb.2014.00542 – volume: 3 start-page: 243 year: 2012 end-page: 250 ident: B23 article-title: Acinetobacter baumannii: an emerging opportunistic pathogen publication-title: Virulence doi: 10.4161/viru.19700 – volume: 58 start-page: 518 year: 2014 end-page: 526 ident: B19 article-title: Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01597-13 – volume: 64 start-page: 357 year: 2010 end-page: 372 ident: B6 article-title: Persister cells publication-title: Annu Rev Microbiol doi: 10.1146/annurev.micro.112408.134306 – volume: 59 start-page: 1983 year: 2015 end-page: 1991 ident: B38 article-title: Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.04641-14 – volume: 45 start-page: 568 year: 2015 end-page: 585 ident: B2 article-title: Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2015.03.001 – volume: 192 start-page: 6191 year: 2010 end-page: 6199 ident: B47 article-title: Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis publication-title: J Bacteriol doi: 10.1128/JB.01651-09 – volume: 40 start-page: 1503 year: 2012 end-page: 1506 ident: B43 article-title: Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis publication-title: Biochem Soc Trans doi: 10.1042/BST20120209 – volume: 30 start-page: 257 year: 2009 end-page: 263 ident: B1 article-title: Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital publication-title: Infect Control Hosp Epidemiol doi: 10.1086/595977 – volume: 8 start-page: 120 year: 2000 end-page: 128 ident: B12 article-title: Phages will out: strategies of host cell lysis publication-title: Trends Microbiol doi: 10.1016/S0966-842X(00)01705-4 – volume: 11 start-page: 297 year: 2013 end-page: 308 ident: B3 article-title: Clinical relevance of the ESKAPE pathogens publication-title: Expert Rev Anti Infect Ther doi: 10.1586/eri.13.12 – volume: 17 start-page: 1586 year: 2015 end-page: 1599 ident: B45 article-title: Metabolite profiling and peptidoglycan analysis of transient cell wall-deficient bacteria in a new Escherichia coli model system publication-title: Environ Microbiol doi: 10.1111/1462-2920.12594 – volume: 339 start-page: 91 year: 2013 end-page: 95 ident: B9 article-title: Dynamic persistence of antibiotic-stressed mycobacteria publication-title: Science doi: 10.1126/science.1229858 |
SSID | ssj0006590 |
Score | 2.535563 |
Snippet | Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However,... |
SourceID | pubmedcentral proquest asm2 pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 3480 |
SubjectTerms | Acinetobacter baumannii Acinetobacter baumannii - drug effects Acinetobacter Infections Acinetobacter Infections - drug therapy Acinetobacter Infections - microbiology Anti-Bacterial Agents Anti-Bacterial Agents - pharmacology Cathelicidins Cathelicidins - pharmacology Drug Resistance, Multiple, Bacterial Edetic Acid - pharmacology Endopeptidases Endopeptidases - chemistry Endopeptidases - pharmacology Experimental Therapeutics Humans Microbial Sensitivity Tests Microfluidic Analytical Techniques Pseudomonadales Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Recombinant Fusion Proteins Recombinant Fusion Proteins - pharmacology |
Title | Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27021321 https://journals.asm.org/doi/10.1128/AAC.00285-16 https://www.proquest.com/docview/1791325882 https://www.proquest.com/docview/1808713537 https://pubmed.ncbi.nlm.nih.gov/PMC4879360 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIhAXBAVKeGlB0Evq4ud6fYxCoQIFBZGi3iyvvW4sESeKk0P4e_wxZrzrtQMtgl4iPzax4_k8j92Zbwh5nThMOHbOLMltbvkRcyxw6pkV2oL5zOe2n2A18vgzOz3zP54H573ez07W0mYtjtMfl9aVXEeqcAzkilWy_yFZ86NwALZBvvAJEobPf5LxCfI_YL92dCfhNNKLlLhlgbkeJBcQ9VeYdVyhk6hzyTHlHUULu0NcVMcXGgmbByLB-fyyKLr-6rBcF_OiJmtCUoGLuh6uLoWbybku3jKT8u9kjg0nVO4sGJ5VYVDzNZ1t0AaUetlhVRhf_sNqCw9suVJT2Xr9w5zEDNNKTV1jGc7g03F3nsJhbT5VpzQAdVYnG3VctGxTXS3NmIUwUTZKKWbkPWWB6n7baG7ViUAjtKuGPV-1h9ImHXb55ebCxRKI4XBU59MGlir77CBnOa-hg0V7ELY7rdE0qYyT8Qhivshj9g1y0w3BgcPMgC8tZT3ctKqD0n-qqb5w-dvuhZGVWl8FvIOkmru7ntIf4c_vWbwdt2h6j9zV8QwdKnDeJz1Z7pNbqsPpdp_cHuvcjX1yOFEs6dsjOm2L_qojekgnLX_69gH51sCaLnJqYE01rKmGNTWwpoAM2sKa7sCaGlg_JGfvT6ajU0u3_7AScOvXlgxCmXGRSbQZSEwIvmbKueOlWQiqRNhRGnhwMBJ-GMjMSYVvJ1nAcu5JLlnkPSJ75aKUjwmNPBFGrmQpczJfeHmS-9znXorxtZcIt09e4ROP9btdxXVo7PIYJBTXEood1ieDRh5xqgn0sY_L9ytGvzGjl4o45opxLxvRxqDZcbkuKeViA_cQRoCGAELgv4wBDYtNNr2wTw4UHMzVGjj1SbgDFDMAmeV3z5TFrGaY14h-cu1vPiV3Wh3wjOytVxv5HLz3tXhRvx2_AIkL79U |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Artilysin+Art-175+against+Resistant+and+Persistent+Acinetobacter+baumannii&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Defraine%2C+Valerie&rft.au=Schuermans%2C+Joris&rft.au=Grymonprez%2C+Barbara&rft.au=Govers%2C+Sander+K.&rft.date=2016-06-01&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=60&rft.issue=6&rft.spage=3480&rft.epage=3488&rft_id=info:doi/10.1128%2FAAC.00285-16&rft_id=info%3Apmid%2F27021321&rft.externalDocID=PMC4879360 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |